Phase 3 EGFR Activating Mutation Clinical Trials
2 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–2 of 2 trials
Recruiting
Phase 3
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NSCLCEGFR Activating Mutation
TYK Medicines, Inc680 enrolled2 locationsNCT05382728
Recruiting
Phase 3
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
Brain MetastasesRadiotherapyEGFR Activating Mutation
Sun Yat-sen University232 enrolled1 locationNCT05768490